



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On December 30, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Sylvia E. Arnold

PATENT
Attorney Docket No.: 10692V-000521US
Client Reference No.: PTQ Ref.: 1007-024-00US

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Michael A. Adams et al.

Application No.: 10/042,039

Filed: October 25, 2001

For: FORMULATIONS AND
METHODS OF USING NITRIC OXIDE
MIMETICS AGAINST A MALIGNANT
CELL PHENOTYPE

Examiner:

Art Unit: 1616

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
JS:cjl
SF 1404634 v1



Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/042,039
Filing Date	October 25, 2001
First Named Inventor	Adams, Michael A.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	10692V-000521US

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
---	---	--

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Joseph R. Snyder	Reg. No. 39,381
Signature		
Date	December 30, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

December 30, 2002

Typed or printed name	Sylvia E. Arnold		
Signature		Date	December 30, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9051265 v1



Under the Paper
Substitute for Form 1449A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	10/042,039
Filing Date	October 25, 2001
First Named Inventor	Adams, Michael A., et. al.
Art Unit	1616
Examiner Name	
Attorney Docket Number	10692V-000521US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant . Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	BA	WO	93/20806	10-28-1993	United States of America, National Institute of Health		<input type="checkbox"/>
	BB	WO	96/15781	05-30-1996	United States of America, National Institute of Health		<input type="checkbox"/>
	BC	WO	98/58633	12-30-1998	Queen's University at Kingston		<input type="checkbox"/>
	BD	WO	99/48916	09-30-1999	The Board of Trustees, Leland Stanford Jr. Univ.		<input type="checkbox"/>


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

SF 1404634 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3**Complete if Known**

Application Number	10/042,039
Filing Date	October 25, 2001
First Named Inventor	Adams, Michael A., et. al.
Art Unit	1616
Examiner Name	
Attorney Docket Number	10692V-000521US

TECH CENTER 160019001
JAN 07 2003

+ RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	BRIZEL et al., "Tumor Hypoxia Adversely Affects the Prognosis of Carcinoma of the Head and Neck", <i>Int. J. Radiation Oncology Biol. Phys.</i> 1997 38(2):285-289	
	CB	BRIZEL et al., "Tumor Oxygenation Predicts for the Likelihood of Distant Metastases in Human Soft Tissue Sarcoma", <i>Cancer Research</i> 1996 56:941-943	
	CC	HARRIS et al., "Breast cancer angiogenesis-new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting", <i>Breast Cancer Research and Treatment</i> 1996 38:97-108	
	CD	HÖCKEL et al., "Association between Tumor Hypoxia and Malignant Progression in Advanced Cancer of the Uterine Cervix", <i>Cancer Research</i> 1996 56:4509-4515	
	CE	KONG et al., "Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules", <i>Clin. Exp. Metastasis</i> 1996 14:335-343	
	CF	MITCHELL et al., "Radiation sensitisation by nitric oxide releasing agents", <i>British Journal of Cancer</i> 1996 74:(Suppl. XXVII) S181-S184	
	CG	MITCHELL et al., "Hypoxic mammalian cell radiosensitization by nitric oxide", <i>Cancer Research</i> 1993 53(24) 5845-5848 (ABSTRACT ONLY)	
	CH	MITCHELL et al., "Hypoxic Mammalian Cell Radiosensitization by Nitric Oxide", <i>Cancer Research</i> 1993 53:5845-5848	
	CI	PIPILI-SYNETOS et al., "Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate", <i>British Journal of Pharmacology</i> 1995 116:1829-1834	
	CJ	TEICHER B.A., "Hypoxia and drug resistance", <i>Cancer and Metastasis Reviews</i> 1994 13:139-168	
	CK	TRIKHA et al., "Nitroglycerin: a NO donor inhibits TPA-mediated tumor promotion in murine skin", <i>Carcinogenesis</i> 2001 22(8):1207-1211	
	CL	WINK et al., "Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide", <i>Free Radic Biol Med</i> 1998 25(4-5):434-456 (ABSTRACT ONLY)	
	CM	WINK et al., "Nitric Oxide and Some Nitric Oxide Donor Compounds Enhance the Cytotoxicity of Cisplatin", <i>Nitric Oxide: Biology and Chemistry</i> 1997 1(1):88-94	
	CN	XIE et al., "Therapy of cancer metastasis by activation of the inducible nitric oxide synthase", <i>Cancer and Metastasis Reviews</i> 1998 17:55-75	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1404634 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
JUN 27 2003

SF 1404634 v1